Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Two Sigma Advisers LP lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 8.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 336,300 shares of the company's stock after selling 30,700 shares during the period. Two Sigma Advisers LP owned about 0.52% of Kymera Therapeutics worth $15,917,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Values First Advisors Inc. purchased a new stake in Kymera Therapeutics in the third quarter worth about $61,000. Quarry LP purchased a new stake in Kymera Therapeutics in the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after acquiring an additional 504 shares during the period. Comerica Bank lifted its holdings in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after purchasing an additional 400 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in shares of Kymera Therapeutics in the second quarter worth approximately $139,000.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 15.82% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on KYMR shares. Leerink Partnrs upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Truist Financial restated a "buy" rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price for the company in a research report on Monday, August 26th. BMO Capital Markets began coverage on Kymera Therapeutics in a research note on Friday. They set a "market perform" rating and a $55.00 target price on the stock. Finally, Wells Fargo & Company raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and an average price target of $53.50.

Kymera Therapeutics Stock Down 6.5 %

KYMR traded down $3.02 on Monday, hitting $43.65. The company had a trading volume of 663,028 shares, compared to its average volume of 582,138. The company has a market cap of $2.83 billion, a PE ratio of -18.53 and a beta of 2.16. The business's fifty day simple moving average is $46.40 and its 200 day simple moving average is $42.64. Kymera Therapeutics, Inc. has a 12-month low of $21.20 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period last year, the company earned ($0.90) earnings per share. Kymera Therapeutics's revenue was down 20.9% on a year-over-year basis. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.